JP7268958B2 - Ｄｎａ抗体構築物及びその使用方法 - Google Patents

Ｄｎａ抗体構築物及びその使用方法 Download PDF

Info

Publication number
JP7268958B2
JP7268958B2 JP2017529013A JP2017529013A JP7268958B2 JP 7268958 B2 JP7268958 B2 JP 7268958B2 JP 2017529013 A JP2017529013 A JP 2017529013A JP 2017529013 A JP2017529013 A JP 2017529013A JP 7268958 B2 JP7268958 B2 JP 7268958B2
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
chikv
antibody
env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537621A5 (cg-RX-API-DMAC7.html
JP2017537621A (ja
Inventor
ビー．ウェイナー デイビッド
ムスマニ カルッピアー
フリンガイ セリーケ
ワイ．サーデサイ ニランジャン
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
イノビオ ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, イノビオ ファーマシューティカルズ，インコーポレイティド filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2017537621A publication Critical patent/JP2017537621A/ja
Publication of JP2017537621A5 publication Critical patent/JP2017537621A5/ja
Priority to JP2022111396A priority Critical patent/JP2022160435A/ja
Application granted granted Critical
Publication of JP7268958B2 publication Critical patent/JP7268958B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
JP2017529013A 2014-12-01 2015-12-01 Ｄｎａ抗体構築物及びその使用方法 Active JP7268958B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022111396A JP2022160435A (ja) 2014-12-01 2022-07-11 Ｄｎａ抗体構築物及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462086157P 2014-12-01 2014-12-01
US62/086,157 2014-12-01
US201562213166P 2015-09-02 2015-09-02
US62/213,166 2015-09-02
PCT/US2015/063174 WO2016089862A1 (en) 2014-12-01 2015-12-01 Dna antibody constructs and method of using same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020201725A Division JP2021052776A (ja) 2014-12-01 2020-12-04 Ｄｎａ抗体構築物及びその使用方法
JP2022111396A Division JP2022160435A (ja) 2014-12-01 2022-07-11 Ｄｎａ抗体構築物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2017537621A JP2017537621A (ja) 2017-12-21
JP2017537621A5 JP2017537621A5 (cg-RX-API-DMAC7.html) 2019-01-17
JP7268958B2 true JP7268958B2 (ja) 2023-05-08

Family

ID=56092325

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017529013A Active JP7268958B2 (ja) 2014-12-01 2015-12-01 Ｄｎａ抗体構築物及びその使用方法
JP2020201725A Pending JP2021052776A (ja) 2014-12-01 2020-12-04 Ｄｎａ抗体構築物及びその使用方法
JP2022111396A Pending JP2022160435A (ja) 2014-12-01 2022-07-11 Ｄｎａ抗体構築物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020201725A Pending JP2021052776A (ja) 2014-12-01 2020-12-04 Ｄｎａ抗体構築物及びその使用方法
JP2022111396A Pending JP2022160435A (ja) 2014-12-01 2022-07-11 Ｄｎａ抗体構築物及びその使用方法

Country Status (11)

Country Link
US (2) US11278619B2 (cg-RX-API-DMAC7.html)
EP (1) EP3226892A4 (cg-RX-API-DMAC7.html)
JP (3) JP7268958B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170085131A (cg-RX-API-DMAC7.html)
CN (2) CN107427566B (cg-RX-API-DMAC7.html)
AU (3) AU2015355126B9 (cg-RX-API-DMAC7.html)
BR (1) BR112017011556A2 (cg-RX-API-DMAC7.html)
CA (1) CA2969214A1 (cg-RX-API-DMAC7.html)
MX (2) MX2017007187A (cg-RX-API-DMAC7.html)
WO (1) WO2016089862A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703710B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
KR20170085131A (ko) * 2014-12-01 2017-07-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Dna 항체 작제물 및 그 이용 방법
US11851477B2 (en) * 2016-05-05 2023-12-26 The Trustees Of The University Of Pennsylvania DNA monoclonal antibodies targeting influenza virus
US11925685B2 (en) * 2016-09-19 2024-03-12 The Trustees Of The University Of Pennsylvania DNA antibody constructs encoding anti-ZIKV envelope antibodies
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
CN116392609A (zh) * 2017-03-23 2023-07-07 Dnarx公司 用于体内核酸表达的系统和方法
EP3601334A4 (en) * 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
JP2020519285A (ja) * 2017-05-10 2020-07-02 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー 最適化された核酸抗体構築物
AU2018280871B2 (en) 2017-06-08 2024-09-26 Black Belt Therapeutics Ltd CD38 modulating antibody
CA3073085A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 modulating antibody
CA3072296A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 antibody
WO2019139648A2 (en) * 2017-09-15 2019-07-18 David Weiner Dna antibody constructs for use against ebola virus
AU2018345715A1 (en) 2017-10-06 2020-05-21 The Wistar Institute Of Anatomy And Biology DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
US12110342B2 (en) 2018-01-31 2024-10-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use
CN111253493B (zh) * 2020-03-05 2021-03-23 武汉科技大学 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用
US11744885B2 (en) 2020-05-14 2023-09-05 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
CN118725096B (zh) * 2024-08-08 2025-02-07 兰州大学 一种ns1蛋白单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530243A (ja) 2005-02-18 2008-08-07 メダレックス， インク． フコシル残基を欠く前立腺特異的膜抗原（ｐｓｍａ）に対するモノクローナル抗体
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2014093894A2 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5914109A (en) * 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
CA2153593C (en) 1993-01-26 2010-04-13 David B. Weiner Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6025158A (en) * 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
WO2000002621A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030073613A1 (en) * 2000-03-22 2003-04-17 Mary Gerritsen Angiogenisis associated proteins, and nucleic acids encoding the same
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
AU2003295366B2 (en) 2002-11-04 2011-11-24 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK2364769T3 (en) 2003-05-30 2016-04-11 Vgxi Inc Apparatus and methods for biomaterialeproduktion
CN1480215A (zh) 2003-07-07 2004-03-10 叶新新 Sars病毒抗原抗体复合疫苗及实验动物模型与方法
KR101282396B1 (ko) 2004-05-28 2013-07-04 어젠시스 인코포레이티드 Ｐｓｃａ 단백질에 결합하는 암 진단용 항체
EP1753871B1 (en) 2004-05-28 2015-07-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
CA2573656A1 (en) 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
US20060216722A1 (en) 2005-03-25 2006-09-28 Christer Betsholtz Glomerular expression profiling
TW200745332A (en) * 2005-07-21 2007-12-16 Abbott Lab Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
JP2009171880A (ja) 2008-01-23 2009-08-06 Yokohama City Univ アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発
NZ587830A (en) 2008-03-14 2012-08-31 Transgene Sa Antibody against the colony-stimulating factor-1 receptor (CSF-1R)
KR101589511B1 (ko) 2008-04-04 2016-02-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 치쿤구니야 바이러스 단백질의 공통 서열, 이를 인코딩하는 핵산 분자, 조성물 및 이를 이용하는 방법
CN108610416B (zh) 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CA2766608C (en) 2009-07-06 2018-06-19 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
RU2553331C2 (ru) 2009-07-13 2015-06-10 Бхарат Байотек Интернэшнл Лимитед Композиция, применимая в качестве ротавирусной вакцины, и способ ее получения
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
US9175070B2 (en) * 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
AU2011325893B2 (en) 2010-11-12 2016-01-14 Inovio Pharmaceuticals, Inc Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
CA2826199A1 (en) 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
BR112013021494B1 (pt) 2011-02-22 2021-09-08 California Institute Of Technology Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
BR112015013004B1 (pt) 2012-12-13 2022-09-06 The Trustees Of The University Of Pennsylvania Molécula de ácido nucleico isolada, proteína e seus usos, bem como composição e vacina
WO2015089492A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
KR20170085131A (ko) * 2014-12-01 2017-07-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Dna 항체 작제물 및 그 이용 방법
EP3830132B1 (en) * 2018-07-31 2022-11-23 Heidelberg Pharma Research GmbH Humanized antibodies against psma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530243A (ja) 2005-02-18 2008-08-07 メダレックス， インク． フコシル残基を欠く前立腺特異的膜抗原（ｐｓｍａ）に対するモノクローナル抗体
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2014093894A2 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same

Also Published As

Publication number Publication date
CN114010802A (zh) 2022-02-08
US20170266282A1 (en) 2017-09-21
AU2019202433A1 (en) 2019-05-02
JP2021052776A (ja) 2021-04-08
JP2022160435A (ja) 2022-10-19
US11278619B2 (en) 2022-03-22
CN107427566B (zh) 2021-08-17
AU2015355126B2 (en) 2019-05-02
CA2969214A1 (en) 2016-06-09
AU2015355126A1 (en) 2017-06-15
AU2021201586A1 (en) 2021-04-01
EP3226892A1 (en) 2017-10-11
EP3226892A4 (en) 2018-07-18
CN107427566A (zh) 2017-12-01
KR20170085131A (ko) 2017-07-21
HK1247100A1 (zh) 2018-09-21
MX2017007187A (es) 2018-01-30
AU2015355126B9 (en) 2020-03-26
MX2023009421A (es) 2023-08-15
WO2016089862A1 (en) 2016-06-09
BR112017011556A2 (pt) 2018-03-06
US20230023093A1 (en) 2023-01-26
ZA201703710B (en) 2020-11-25
JP2017537621A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
JP7268958B2 (ja) Ｄｎａ抗体構築物及びその使用方法
JP2023080085A (ja) Ｄｎａ抗体構築物およびその使用方法
JP2021166534A (ja) Ｄｎａ抗体構築物及びその使用方法
JP7078350B2 (ja) Ｄｎａ抗体構築物及びその使用方法
HK1247100B (zh) Dna抗体构建体及其使用方法

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201204

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201204

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210226

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210302

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210507

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210511

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210831

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211012

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220408

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220802

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230221

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230328

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230421

R150 Certificate of patent or registration of utility model

Ref document number: 7268958

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150